Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Seagen Inc v. Daiichi Sankyo Co Ltd
Case Number:
2:22-cv-01613
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 02, 2024
Daiichi Gets Award Nixing Seagen Cancer Drug Claims OK'd
A Washington federal judge has refused to revive U.S. biotech company Seagen Inc.'s claims seeking billions of dollars in damages in a dispute with Japanese drugmaker Daiichi Sankyo Co. Ltd. over cancer drug patents, ruling that an arbitrator who tossed the claims did not disregard the law.
-
March 12, 2024
Daiichi Urges Court To OK Arbitrator's Award Against Seagan
Japanese drugmaker Daiichi Sankyo has asked a Seattle federal judge not to toss an arbitral award refusing Seagen Inc.'s claims for billions of dollars in a dispute over cancer drug patents, saying the U.S. biotech company has incorrectly lodged a petition to vacate the award.
-
December 04, 2023
Seagen Looks To Revive Cancer Drug Claims In Daiichi Fight
U.S. biotech company Seagen Inc. will look to revive its claims seeking billions of dollars in damages in a dispute with Japanese drugmaker Daiichi Sankyo Co. Ltd. over cancer drug patents, arguing that an arbitrator disregarded the "language and essence" of an underlying collaboration agreement.
-
November 28, 2023
Daiichi Awarded $46M Fees In Cancer Drug Patent Arbitration
Japanese drugmaker Daiichi Sankyo Ltd. has scored nearly $46 million in fees and costs in an arbitration initiated by rival Seagen in the companies' patent dispute over cancer drug technology after the arbitrator found that the U.S. biotech company did not file its infringement claims within the six-year statute of limitations.
-
January 20, 2023
Daiichi Slams Seagen's Bid To Nix Cancer Drug Patent Award
Japanese drugmaker Daiichi Sankyo urged a federal court to uphold an arbitral award nixing U.S. biotechnology company Seagen's claims seeking tens of billions of dollars in a dispute over cancer drug patents, arguing Seagen is making "unfounded scattershot attacks" on the award.
-
November 15, 2022
Seagen Looks To Nix Daiichi Win In Cancer Drug Dispute
U.S. biotechnology company Seagen is looking to vacate an arbitral award nixing its claim to patents for technology used in cancer drugs filed by Japanese drugmaker Daiichi Sankyo Ltd. after their seven-year collaboration ended, calling the award "irrational" and saying the arbitrator disregarded the law.